SCHEMBL14019201

SCHEMBL14019201

CCOC(=O)/C(O)=C(\C)C#N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
TSHR P16473 1/20 0.53
CYP2C9 P11712 1/20 0.46
MAPT P10636 5/20 0.44
KDM4E B2RXH2 4/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GLO1 Q04760 1/20 0.41
NPSR1 Q6W5P4 2/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EGLN1 Q9GZT9 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15055595 1.00 ALDH1A1 (0.53) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL27889490 0.81 ALDH1A1 (0.55) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL13664238 0.81 ALDH1A1 (0.55) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL28166960 0.80 ALDH1A1 (0.50) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL16043759 0.79 ALDH1A1 (0.53) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL13237294 0.79 ALDH1A1 (0.53) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL24014841 0.78 ALDH1A1 (0.52) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL16534922 0.78 ALDH1A1 (0.52) ALDH1A1TSHRCYP2C9MAPTKDM4E
SCHEMBL5496037 0.77 ALDH1A1 (0.53) ALDH1A1TSHRMAPTKMT2AMEN1
SCHEMBL14809891 0.76 ALDH1A1 (0.50) ALDH1A1TSHRCYP2C9MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794596-B1 SUBSTITUTED BENZYLPYRAZOLES BAYER IP GMBH (DE) 2017-05-31 EP disclosed
EP-2794596-B1 SUBSTITUTED BENZYLPYRAZOLES BAYER IP GMBH (DE) 2017-05-31 EP disclosed
US-9643953-B2 Substituted benzylpyrazoles BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-05-09 US disclosed
US-9643953-B2 Substituted benzylpyrazoles BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-05-09 US disclosed
US-9643953-B2 Substituted benzylpyrazoles BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-05-09 US disclosed
US-9422268-B2 2016-08-23 US disclosed
US-9422268-B2 2016-08-23 US disclosed
US-9422268-B2 2016-08-23 US disclosed
EP-2794596-A1 SUBSTITUTED BENZYLPYRAZOLES Bayer Intellectual Property GmbH (DE) 2014-10-29 EP disclosed
US-20140315934-A1 SUBSTITUTED BENZYLPYRAZOLES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-23 US disclosed
US-20140315934-A1 SUBSTITUTED BENZYLPYRAZOLES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-23 US disclosed
US-20140315934-A1 SUBSTITUTED BENZYLPYRAZOLES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-23 US disclosed
WO-2013092512-A1 SUBSTITUTED BENZYLPYRAZOLES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-27 WO disclosed
WO-2013092512-A1 SUBSTITUTED BENZYLPYRAZOLES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-27 WO disclosed
US-7432379-B2 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. (US) 2008-10-07 US disclosed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed
US-20070161633-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2007-07-12 US disclosed
US-20070123531-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123531-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, LTB4R ALDH1A1 1890/4885TSHR 1097/4885CYP2C9 1295/4885
US-20070161633-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, HRH2 ALDH1A1 1736/4885TSHR 1217/4885CYP2C9 804/4885
US-20140315934-A1 SUBSTITUTED BENZYLPYRAZOLES CYP3A43, CYP3A7, ABCB1 ALDH1A1 440/4885TSHR 3073/4885CYP2C9 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.